Us Congress 2025-2026 Regular Session

Us Congress House Bill HB654

Introduced
1/23/25  

Caption

TABS Act of 2025 Taking Account of Bureaucrats’ Spending Act of 2025

Impact

The legislative changes outlined in HB654 will significantly impact existing state and federal financial regulations. By rebranding the Bureau to the Consumer Financial Empowerment Agency, the bill aims to ensure that the new agency is better positioned to address consumer issues, possibly leading to more robust protection regulations. The shift to an independent agency structure is expected to change operational dynamics, with potential implications on how financial products are regulated and consumer complaints are handled across various platforms. Additionally, the amendment to the funding process is designed to enhance fiscal responsibility, ensuring that taxpayer dollars are managed with more scrutiny.

Summary

House Bill 654, also known as the 'Taking Account of Bureaucrats’ Spending Act of 2025' or the 'TABS Act of 2025', proposes to transform the Bureau of Consumer Financial Protection into an independent agency called the Consumer Financial Empowerment Agency. This change is aimed at enhancing the accountability and operational transparency of the Bureau by subjecting it to the regular appropriations process, thereby giving Congress more oversight over its funding and expenditure decisions. The bill seeks to clearly delineate the roles and responsibilities of the new Agency compared to its predecessor, promoting consumer financial empowerment under more direct governmental oversight.

Contention

The transition from the Bureau to the Consumer Financial Empowerment Agency has been met with mixed reactions among lawmakers and consumer advocacy groups. Proponents argue that creating an independent agency will enhance budgeting transparency and provide a stronger framework for protecting consumers, particularly in regulating mortgages and credit options. However, critics express concern that this transition may dilute the Bureau's mission, potentially leading to less stringent oversight of financial institutions, which could, in turn, risk consumer financial protections already established. This ongoing debate reflects broader tensions between enhancing agency accountability and maintaining sufficient oversight to protect consumer interests.

Congress_id

119-HR-654

Policy_area

Finance and Financial Sector

Introduced_date

2025-01-23

Companion Bills

No companion bills found.

Similar Bills

US SB331

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US SB300

DLARA Disaster Loan Accountability and Reform Act

US HB2031

HOME Investment Partnerships Reauthorization and Improvement Act of 2025

US HB1048

Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions Act or the DETERRENT ActThis bill expands oversight and disclosure requirements related to foreign sources and institutions of higher education (IHEs).Specifically, the bill requires an IHE to annually disclose to the Department of Education (ED) any year in which the IHEreceives a gift from a foreign country of concern (e.g., China or Russia) or foreign entity of concern of any dollar amount;receives a gift or contract from a foreign source (other than a foreign country of concern or foreign entity of concern) that is valued at $50,000 or more, considered alone or in combination with all other gifts or contracts within a calendar year (current disclosure threshold is $250,000 or more), or which has an undetermined monetary value;enters into a contract with a foreign country of concern or foreign entity of concern after receiving a waiver for such contract; oris substantially controlled by a foreign source.Additionally, the billprohibits IHEs from entering into contracts with a foreign country of concern or with a foreign entity of concern without obtaining a waiver,requires certain IHEs to disclose gifts or contracts between covered individuals (e.g., researchers) and foreign sources, andrequires private IHEs with specified assets or investments to file annual investment disclosure reports.The bill requires ED to investigate possible violations of this bill and outlines the various penalties for each violation. Penalties may include losing eligibility for federal student financial aid.

US SB93

Harmful Algal Bloom and Hypoxia Research and Control Amendments Act of 2025

US HB644

Harmful Algal Bloom and Hypoxia Research and Control Amendments Act of 2025

US SB445

Carried Interest Fairness Act of 2025

US HB27

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.